Sec Form 13D Filing - Novartis Bioventures Ltd filing for Aadi Bioscience Inc. (AADI) - 2019-04-29

Under the Securities Exchange Act of 1934
(Amendment No. 4)*

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(1)   Based on 40,588,004 shares of Common Stock outstanding as of March 1, 2019, as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2019.

2

(1)   Based on 40,588,004 shares of Common Stock outstanding as of March 1, 2019, as reported in the Issuer’s Annual Report on Form 10-K filed with the SEC on March 7, 2019.

3

Item 1.                              Security and Issuer.

This Amendment No. 4 (the “Amendment”) to Schedule 13D amends the Schedule 13D filed by the Reporting Persons (as defined below) with the SEC on March 27, 2017, as previously amended on June 28, 2018,  March 28, 2019 and April 11, 2019 (the “Original Schedule 13D” and, together with the Amendment, the “Schedule 13D”) and relates to the common stock, par value $0.0001 per share (the “Common Stock”), of Aerpio Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).  The address of the Issuer’s principal executive office is 9987 Carver Road, Cincinnati, OH 45242.

Except as otherwise described herein, the information contained in the Original Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth with respect thereto in the Original Schedule 13D.

Item 2.                              Identity and Background.

No changes.

Item 3.                              Source and Amounts of Funds or Other Consideration.

No changes.

Item 4.                              Purpose of Transaction.

The information set forth in Item 5(c) of this Amendment is incorporated herein by reference. Otherwise, there are no changes to the disclosure provided under this Item 4 in the Original Schedule 13D.

Item 5.                              Interest in Securities of the Issuer.

No changes except as described below.

(a)            Based on 40,588,004 shares of Common Stock outstanding as of March 1, 2019, as reported in the Issuer’s Annual Report on Form 10-K filed with the SEC on March 7, 2019, the Common Stock held by the Reporting Persons constitutes 9.98% of the outstanding shares of Common Stock of the Issuer.

(b)            With respect to the number of shares of Common Stock as to which each Reporting Person has:

(i)                                     sole power to vote or to direct the vote with respect to such shares of Common Stock, please see row 7 of the applicable cover sheet to this Amendment for such Reporting Person;

(ii)                                  shared power to vote or to direct the vote with respect to such shares of Common Stock, please see row 8 of the applicable cover sheet to this Amendment for such Reporting Person;

(iii)                               sole power to dispose or direct the disposition of such shares of Common Stock, please see row 9 of the applicable cover sheet to this Amendment for such Reporting Person; and

(iv)                              shared power to dispose or to direct the disposition of such shares of Common Stock, please see row 10 of the applicable cover sheet to this Amendment for such Reporting Person.

(c)             Other than the open market sales referred to below or previously reported in the Original Schedule 13D, none of (i) the Reporting Persons or, (ii) to the Reporting Persons’ knowledge, the persons set forth on Schedule I hereto has effected any transaction in the Common Stock during the past 60 days.

On April 26, 2019, the Reporting Persons sold 138,704 shares of Common Stock at a weighted average price of $1.03 per share (price range: $1.02 - $1.05).

On April 25, 2019, the Reporting Persons sold 563,096 shares of Common Stock at a weighted average price of $1.03 per share (price range: $1.00 - $1.04).

On April 24, 2019, the Reporting Persons sold 16,403 shares of Common Stock at a weighted average price of $1.03 per share (price range: $1.03 - $1.06).

On April 23, 2019, the Reporting Persons sold 27,554 shares of Common Stock at a weighted average price of $1.03 per share (price range: $0.99 - $1.06).

4

On April 22, 2019, the Reporting Persons sold 7,100 shares of Common Stock at a weighted average price of $0.97 per share (price range: $0.95 - $0.99).

On April 15, 2019, the Reporting Persons sold 28,794 shares of Common Stock at a weighted average price of $0.99 per share (price range: $0.97 - $1.03).

On April 12, 2019, the Reporting Persons sold 30,908 shares of Common Stock at a weighted average price of $1.04 per share (price range: $1.02 - $1.08).

On April 11, 2019, the Reporting Persons sold 57,438 shares of Common Stock at a weighted average price of $1.08 per share (price range: $1.03 - $1.15).

The Reporting Persons undertake to provide the Issuer, any stockholder of the Issuer, or the Staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Item 5(c).

(d)            Not applicable.

(e)             Not applicable.

Item 6.                              Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

No changes.

Item 7.                              Material to be Filed as Exhibits.

5

Signature

After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

6